Asked by: Andrew Rosindell (Conservative - Romford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to support research on (a) the causes of and (b) treatments for acute myeloid leukaemia.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests £1.5 billion per year on health research, through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group.
The Government, through the NIHR, is committed to improving research into cancers with the poorest survival rates, such as acute myeloid leukaemia, by funding high quality, timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers. The following table shows NIHR research spend on diagnosis, treatment, and both diagnosis and treatment of blood cancers, including leukaemia, since 2018:
| Number of projects | Total awards value |
Blood cancer diagnosis | 11 | £11,900,000 |
Blood cancer treatment | 14 | £14,700,000 |
Blood cancer diagnosis and treatment | 4 | £7,700,000 |
In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including acute myeloid leukaemia. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.
Asked by: Josh MacAlister (Labour - Whitehaven and Workington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure sufficient supply of (a) creon and (b) other ADHD medications.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply whilst stocks are limited.
The Department has also been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are also impacting countries throughout Europe. As a result of intensive work, some issues have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available. We are working to resolve the remaining issues impacting some strengths of methylphenidate. This includes asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.
The Department has worked with specialist clinicians to develop management advice for clinicians which includes consideration to prescribe available alternative brands of methylphenidate prolonged release tablets. We have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping to ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.
Asked by: Dan Carden (Labour - Liverpool Walton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve pancreatic cancer outcomes.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is working with NHS England to deliver interventions to improve outcomes for those with pancreatic cancer across England. Early diagnosis is imperative to improving outcomes for all types of cancer, especially pancreatic due to the non-specific nature of its symptoms. As the first step to ensuring faster diagnosis and treatment, we will deliver an extra 40,000 operations, scans, and appointments each week.
For pancreatic cancer specifically, NHS England is providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer. NHS England is additionally creating pathways to support faster referral routes for people with non-specific symptoms, and is increasing direct access for general practitioners to diagnostic tests.
Additionally, the Getting it Right First-Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight good practice and actions National Health Service providers need to take to improve services. NHS England is also funding a new audit into pancreatic cancer, aiming to provide regular and timely evidence to cancer service providers of where patterns of care in England may vary, to increase the consistency of access to treatments and to stimulate improvements in cancer treatment and outcomes for patients.
Asked by: Mark Pritchard (Conservative - The Wrekin)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure adequate supplies of pancreatic enzyme replacement therapy medication.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.
Asked by: Peter Swallow (Labour - Bracknell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the availability of Creon to treat Type 2 diabetes.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used by patients with conditions such as type 2 diabetes, cystic fibrosis, and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and help mitigate risks to patients.
Asked by: Mark Pritchard (Conservative - The Wrekin)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the early (a) diagnosis and (b) treatment of pancreatic cancer.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is delivering a range of interventions that are expected to improve early diagnosis and treatment for patients with suspected and diagnosed pancreatic cancer. For early diagnosis, this includes providing a route into pancreatic cancer surveillance for those patients at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner. New pathways are being created to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types. General practice direct access to diagnostic tests is also being increased.
To improve the consistency of access to treatments, NHS England is funding an audit into pancreatic cancer which aims to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024.
NHS England’s Getting it Right First Time programme has also appointed a team of five specialist clinicians to lead a national review into services for pancreatic cancer patients in England. The workstream supports the delivery of the Optimal Care Pathway, a Pancreatic Cancer UK-led initiative which has brought together 300 health professionals and people affected to agree on how standards of diagnosis, treatment, and care of those patients with pancreatic cancer and their families can be improved, as well as gathering examples of good practice to share.
Asked by: Sonia Kumar (Labour - Dudley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he plans to take to tackle pancreatic cancer.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is delivering a range of interventions that are expected to improve early diagnosis and treatment for patients with suspected and diagnosed pancreatic cancer. For early diagnosis, this includes providing a route into pancreatic cancer surveillance for those patients at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner. New pathways are being created to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types. General practice direct access to diagnostic tests is also being increased.
To improve the consistency of access to treatments, NHS England is funding an audit into pancreatic cancer which aims to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024.
NHS England’s Getting it Right First Time programme has also appointed a team of five specialist clinicians to lead a national review into services for pancreatic cancer patients in England. The workstream supports the delivery of the Optimal Care Pathway, a Pancreatic Cancer UK-led initiative which has brought together 300 health professionals and people affected to agree on how standards of diagnosis, treatment, and care of those patients with pancreatic cancer and their families can be improved, as well as gathering examples of good practice to share.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of diagnosis rates for pancreatic cancer in the last 12 months.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
We will improve cancer survival rates by hitting all National Health Service cancer waiting time targets within five years, including for pancreatic cancer. We know that pancreatic cancer is difficult to diagnose due to the non-specific nature of its symptoms. To improve diagnosis and outcomes, NHS England is delivering a range of interventions including implementing non-specific symptom pathways for patients who have symptoms that do not align to a single tumour type, as is often the case with pancreatic cancer. 96 pathways are in place, and more are being introduced. NHS England is also increasing general practice direct access to diagnostic tests, alongside providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer and diagnose cancers sooner.
The most recent Faster Diagnosis Standard performance for upper gastrointestinal cancers, including oesophageal cancer, stomach cancer, small bowel cancer, pancreatic cancer, liver cancer and cancers of the biliary system, is 76% against the 75% standard for May 2024.
Asked by: Sorcha Eastwood (Alliance - Lagan Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that (a) pancreatic cancer and (b) cystic fibrosis patients have access to Creon.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.
Asked by: Chris Bloore (Labour - Redditch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.